Role for MKL1 in megakaryocytc maturation

Blood

Volumn 113, Issue 12, 2009, Pages 2826-2834

  Cheng, Ee Chun ^a   Luo, Qing ^a,b   Bruscia, Emanuela M ^a   Renda, Matthew J ^a   Troy, James A ^a   Massaro, Stephanie A ^a   Tuck, David ^a   Schulz, Vincent ^a   Mane, Shrikant M ^c   Berliner, Nancy ^d   Sun, Yi ^e   Morris, Stephan W ^e   Qiu, Caihong ^a   Krause, Diane S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHONGQING UNIVERSITY   (China)

^c YALE UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIBODY; MKL1 PROTEIN; MYOCARDIN; PHORBOL 13 ACETATE 12 MYRISTATE; SERUM RESPONSE FACTOR; THROMBOPOIETIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; HYBRID PROTEIN; MKL1 PROTEIN, HUMAN; MKL1 PROTEIN, MOUSE; ONCOPROTEIN; SMALL INTERFERING RNA; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CELL COUNT; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; ERYTHROLEUKEMIA CELL; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KNOCKOUT MOUSE; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOUSE; NONHUMAN; PLOIDY; PRIORITY JOURNAL; THROMBOCYTE COUNT; UPREGULATION; ANIMAL; BIOSYNTHESIS; BLOOD; BLOOD CELL COUNT; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DNA MICROARRAY; DRUG EFFECT; ERYTHROLEUKEMIA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; TUMOR CELL LINE;

ANIMALS; BLOOD CELL COUNT; BONE MARROW; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLS, CULTURED; DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MEGAKARYOCYTES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; PLOIDIES; RECOMBINANT FUSION PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SERUM RESPONSE FACTOR; THROMBOCYTOPENIA; THROMBOPOIESIS; THROMBOPOIETIN; TRANS-ACTIVATORS;

EID: 63849253049     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-09-180596     Document Type: Article

References (51)

1. Hitzler JK. Acute megakaryoblastic leukemia in Down syndrome. Pediatr Blood Cancer. 2007;49: 1066-1069.
2. Simon JH, Tebbi CK, Freeman AI, Brecher ML, Green DM, Sandberg AA. Acute megakaryoblastic leukemia associated with mosaic Down's syndrome. Cancer. 1987;60:2515-2520.
3. Carroll A, Civin C, Schneider N, et al. The t(1;22)p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study. Blood. 1991;78: 748-752.
4. Lion T, Haas OA. Acute megakaryocytic leukemia with the t(1;22)(p13;q13). Leuk Lymphoma. 1993; 11:15-20.
5. Lion T, Haas OA, Harbott J, et al. The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children. Blood. 1992;79:3325-3330.
6. Mercher T, Coniat MB, Monni R, et al. Involvement of a human gene related to the Drosophila spengene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia. Proc Natl Acad Sci U S A 2001;98:5776-5779.
7. Ma Z, Morris SW, Valentine V, et al. Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet. 2001;28:220-221.
8. Wickrema A, Crispino JD. Erythroid and megakaryocytic transformation. Oncogene. 2007 26:6803-6815.
9. Raffel GD, Mercher T, Shigematsu H, et al. Ott1(Rbm15) has pleiotropic roles in hematopoietic development. Proc Natl Acad Sci U S A. 2007;104:6001-6006.
10. Ma X, Renda MJ, Wang L, et al. Rbm15 modulates Notch-induced transcriptional activation and affects myeloid differentiation. Mol Cell Biol. 2007;27:3056-3064.
11. Cen B, Selvaraj A, Prywes R. Myocardin/MKL family of SRF coactivators: key regulators of immediate early and muscle specific gene expression. J Cell Biochem. 2004;93:74-82.
12. Cen B, Selvaraj A, Burgess RC, et al. Megakaryo blastic leukemia 1, a potent transcriptional coactivator for serum response factor (SRF), is required for serum induction of SRF target genes. Mol Cell Biol. 2003;23:6597-6608.
13. Du KL, Chen M, Li J, Lepore JJ, Mericko P, Parmacek MS. Megakaryoblastic leukemia factor-1 transduces cytoskeletal signals and induces smooth muscle cell differentiation from undifferentiated embryonic stem cells. J Biol Chem. 2004;279:17578-17586.
14. Selvaraj A, Prywes R. Megakaryoblastic leukemia-1/2, a transcriptional co-activator of serum response factor, is required for skeletal myogenic differentiation. J Biol Chem. 2003;278:41977-41987.
15. Miralles F, Posern G, Zaromytidou AI, Treisman R. Actin dynamics control sRf activity by regulation of its coactivator MAL. Cell. 2003;113:329-342.
16. Vartiainen MK, Guettler S, Larijani B, Treisman R. Nuclear actin regulates dynamic subcellular localization and activity of the SRF cofactor MAL. Science. 2007;316:1749-1752.
17. Sasazuki T, Sawada T, Sakon S, et al. Identification of a novel transcriptional activator, BSAC, by a functional cloning to inhibit tumor necrosis factor-induced cell death. J Biol Chem. 2002;277: 28853-28860.
18. Morita T, Mayanagi T, Sobue K. Dual roles of myocardin-related transcription factors in epithelial mesenchymal transition via slug induction and actin remodeling. J Cell Biol. 2007;179:1027-1042.
19. Sun Y, Boyd K, Xu W, et al. Acute myeloid leukemia-associated Mkl1 (Mrtf-a) is a key regulator of mammary gland function. Mol Cell Biol. 2006;26: 5809-5826.
20. Li S, Chang S, Qi X, Richardson JA, Olson EN. Requirement of a myocardin-related transcription factor for development of mammary myoepithelial cells. Mol Cell Biol. 2006;26:5797-5808.
21. Pronk CJ, Rossi DJ, Mansson R, et al. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell. 2007;1:428-442.
22. Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood. 2008;111:981-986.
23. Italiano JE Jr, Patel-Hett S, Hartwig JH. Mechanics of proplatelet elaboration. J Thromb Haemost. 2007;5[Suppl 1]:18-23.
24. Drachman JG, Sabath DF, Fox NE, Kaushansky K. Thrombopoietin signal transduction in purified murine megakaryocytes. Blood. 1997;89:483-492.
25. Wettenhall JM, Smyth GK. limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics. 2004;20:3705-3706.
26. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.
27. Yang YH, Speed T. Design and Analysis of Comparative Microarray Experiments. New York, NY: Routledge; 2003.
28. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:3.
29. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B. 1995;57: 289-300.
30. Ravid K, Lu J, Zimmet JM, Jones MR. Roads to polyploidy: the megakaryocyte example. J Cell Physiol. 2002;190:7-20.
31. Long MW, Heffner CH, Williams JL, Peters C, Prochownik EV. Regulation of megakaryocyte phenotype in human erythroleukemia cells. J Clin Invest. 1990;85:1072-1084.
32. Cupit LD, Schmidt VA, Gnatenko DV, Bahou WF. Expression of protease activated receptor 3 (PAR3) is upregulated by induction of mega- karyocyte phenotype in human erythroleukemia (HEL) cells. Exp Hematol. 2004;32:991-999.
33. Zweegman S, Veenhof MA, Huijgens PC, Schuurhuis GJ, Drager AM. Regulation of megakaryocytopoiesis in an in vitro stroma model: preferential adhesion of megakaryocytic progenitors and subsequent inhibition of maturation. Exp Hematol. 2000;28:401-410.
34. Miano JM, Long X, Fujiwara K. Serum response factor: master regulator of the actin cytoskeleton and contractile apparatus. Am J Physiol Cell Physiol. 2007;292:C70-C81.
35. Selvaraj A, Prywes R. Expression profiling of serum inducible genes identifies a subset of SRF target genes that are MKL dependent. BMC Mol Biol. 2004;5:13.
36. Sun Q, Chen G, Streb JW, et al. Defining the mammalian CArGome. Genome Res. 2006;16: 197-207.
37. Raslova H, Kauffmann A, Sekkai D, et al. Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach. Blood. 2007;109:3225-3234.
38. Balduini A, d'Apolito M, Arcelli D, et al. Cord blood in vitro expanded CD41 cells: identification of novel components of megakaryocytopoiesis. J Thromb Haemost. 2006;4:848-860.
39. Komor M, Guller S, Baldus CD, et al. Transcriptional profiling of human hematopoiesis during in vitro lineage-specific differentiation. Stem Cells. 2005;23:1154-1169.
40. National Center for Biotechnology Information. GEO: Gene Expression Omnibus. Accession GSE13710. http://www.ncbi.nlm.nih.gov/geo/. Accessed December 10, 2008.
41. Kuter DPH, Sheridan WP, Zucker-Franklin D. Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical, and Clinical Biology. Totowa, NJ: Springer-Verlag; 1997.
42. Miano JM. Serum response factor: toggling between disparate programs of gene expression. J Mol Cell Cardiol. 2003;35:577-593.
43. Owens GK. Molecular control of vascular smooth muscle cell differentiation and phenotypic plasticity. Novartis Found Symp. 2007;283:174-191 [discussion 191-173, 238-141].
44. Nagata Y, Jones MR, Nguyen HG, et al. Vascular smooth muscle cell polyploidization involves changes in chromosome passenger proteins and an endomitotic cell cycle. Exp Cell Res. 2005; 305:277-291.
45. Piekny A, Werner M, Glotzer M. Cytokinesis: welcome to the Rho zone. Trends Cell Biol. 2005;15: 651-658.
46. Lordier L, Jalil A, Aurade F, et al. Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling. Blood. 2008;112:3164-3174.
47. Muntean AG, Pang L, Poncz M, Dowdy SF, Blobel GA, Crispino JD. Cyclin D-Cdk4 is regulated by GATA-1 and required for megakaryocyte growth and polyploidization. Blood. 2007;109: 5199-5207.
48. Ochs HD, Slichter SJ, Harker LA, Von Behrens WE, Clark RA, Wedgwood RJ. The Wiskott- Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets. Blood. 1980;55:243-252.
49. Sabri S, Foudi A, Boukour S, et al. Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. Blood. 2006;108: 134-140.
50. Thrasher AJ, Burns S, Lorenzi R, Jones GE. The Wiskott-Aldrich syndrome: disordered actin dynamics in haematopoietic cells. Immunol Rev. 2000;178:118-128.
51. Descot A, Rex-Haffner M, Courtois G, et al. OTT- MAL is a deregulated activator of serum response factor-dependent gene expression. Mol Cell Biol. 2008;28:6171-6181.